NEW YORK, March 13 - Compugen and biotech company DiagnoCure have won an $800,000 grant from the Canada-Israel Industrial Research and Development Foundation to create a nucleic-acid probe-based diagnostic for lung cancer.
DiagnoCure, based in Quebec City, and Compugen, of Tel Aviv, announced in January their plans to co-develop and commercialize molecular-diagnostic tests that may help researchers detect certain epithelial cancers, such as lung cancer.
Terms of that agreement call for Compugen to identify and validate disease markers. DiagnoCure, meanwhile, brings to the table its experience in developing, manufacturing, and commercializing molecular-diagnostic assays.
Financial details of the deal were not disclosed.
The CIIRDF was established to "promote collaborative R&D between companies in Canada and Israel, by providing information to firms in both countries on R&D partnering potential, and by supporting national industrial R&D initiatives through its funding contribution," the group said in a statement.
"The DiagnoCure-Compugen lung cancer project is exactly the kind of high potential initiative that we look to support," Henri Rothschild, president of the CIIRDF, said in the statement.